The MASAC Recommendations Regarding Physical Therapy Management for the Care of Persons with Congenital Bleeding Disorders provides comprehensive information to assist Physical Therapists at all levels in caring for persons with bleeding disorders (…
For the past four years, Marble Slab Creamery locations in the metro Charlotte region have partnered with NBDF to fundraise for inheritable blood disorders. Every summer, locations rally around Marble Slab Creamery franchisee, Ryan Griffith, his son…
The family of George King reflect on their longtime involvement with the foundation, and how their personal connection to the blood/bleeding disorders community has inspired their work.
Kelly Wornall, Granddaughter of George King…
A review published in the Journal of Thrombosis and Haemostasis (JTH) suggests gene therapy as a potential novel approach to achieving immune tolerance induction (ITI) in patients with hemophilia A and an inhibitor to factor VIII (FVIII). The…
Corporate Giving 101Speaker: Teecee HutchersonNHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research, breakthrough developments,…
Gene EditingSpeaker: Julian GilmoreNHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest in research, breakthrough developments, and more.…
A new illustrated review published in the journal Research and Practice in Thrombosis and Haemostasis makes the case that many established reference intervals (RIs) used to interpret the results of laboratory tests are biased and highly problematic…
Dear Valued Partners, Recently Dr. Len Valentino, President and CEO of the National Hemophilia Foundation, announced his retirement at the end of 2023 and the search for a new leader has begun. Under Dr. Valentino’s leadership, NHF has taken…
The BDRC (formerly the NRB) is organized to enable people affected by inherited bleeding disorders and their loved ones – recognized as lived experience experts (LEEs) – to actively participate and influence the direction of transformational…
CSL Behring has announced that the first patient has been dosed with HEMGENIX®, the only hemophilia B gene therapy product currently approved in the U.S.
Approved by the U.S. Food and Drug Administration in November 2022, HEMGENIX is indicated…